Compare Amphastar Pharmaceuticals Inc (AMPH) vs Procter & Gamble Co (PG) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Procter & Gamble (PG) trades at $147.04, up 0.13% on the day, with technical indicators showing a bearish short-term trend. The stock exhibits strong fundamentals, including consistent earnings beats, a 19.16% net income margin, and a 53.85% analyst buy rating. Recent corporate actions include a $1.09 dividend payment scheduled for May 15, 2026. Cash flow trends indicate stable operations, with 2025 operating cash flow at $17.82 billion.

PG offers a stable investment with dividend growth and operational resilience, but faces risks from premium valuation and modest revenue growth. The consensus price target of $159.75 suggests 8.6% upside, though near-term technical pressure and competitive pressures warrant caution. Long-term investors may find value in its consistent profitability and dividend history.